megaxin iv
bayer israel ltd - moxifloxacin as hydrochloride - solution for infusion - moxifloxacin as hydrochloride 1.6 mg/ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.
moxifloxacin anfarm 400 mg/250 ml solution for infusion
anfarm hellas s.a. 4 achaias str. & trizinias 14564 kifissia, attiki, greece - moxifloxacin hydrochloride - solution for infusion - moxifloxacin hydrochloride 400/250 mg/ml - antibacterials for systemic use
moxifloxacin tablet, film coated
redpharm drug, inc. - moxifloxacin hydrochloride (unii: c53598599t) (moxifloxacin - unii:u188xyd42p) - moxifloxacin hydrochloride tablets are indicated in adult patients for the treatment of community acquired pneumonia caused by susceptible isolates of streptococcus pneumoniae (including multi-drug resistant streptococcus pneumoniae [mdrsp]), haemophilus influenzae, moraxella catarrhalis, methicillin-susceptible staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae, or chlamydophila pneumoniae [see clinical studies ( 14.3) ]. mdrsp isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [mic] ≥ 2 mcg/ml), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. moxifloxacin hydrochloride tablets are indicated in adult patients for the treatment of uncomplicated skin and skin structure infections caused by susceptible isolates of methicillin-susceptible
moxifloxacin 400 mg/250 ml solution for infusion, kabipac bottles
fresenius kabi deutschland gmbh - moxifloxacin - solution for infusion - 400/250 milligram(s)/millilitre - fluoroquinolones; moxifloxacin
moxifloxacin 400 mg/250 ml solution for infusion, freeflex bags
fresenius kabi deutschland gmbh - moxifloxacin - solution for infusion - 400/250 milligram(s)/millilitre - fluoroquinolones; moxifloxacin
teva-moxifloxacin solution
teva canada limited - moxifloxacin (moxifloxacin hydrochloride) - solution - 0.5% - moxifloxacin (moxifloxacin hydrochloride) 0.5% - antibacterials
ag-moxifloxacin solution
angita pharma inc. - moxifloxacin (moxifloxacin hydrochloride) - solution - 0.5% - moxifloxacin (moxifloxacin hydrochloride) 0.5% - antibacterials
priva-moxifloxacin tablet
pharmapar inc - moxifloxacin (moxifloxacin hydrochloride) - tablet - 400mg - moxifloxacin (moxifloxacin hydrochloride) 400mg - quinolones
act moxifloxacin solution
teva canada limited - moxifloxacin (moxifloxacin hydrochloride) - solution - 0.5% - moxifloxacin (moxifloxacin hydrochloride) 0.5% - antibacterials
dom-moxifloxacin tablet
dominion pharmacal - moxifloxacin (moxifloxacin hydrochloride) - tablet - 400mg - moxifloxacin (moxifloxacin hydrochloride) 400mg - quinolones